Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pharmacia & Upjohn licenses Gilead's Vistide ex-US

Executive Summary

Pharmacia & Upjohn has licensed the exclusive, worldwide rights outside the US to Gilead Sciences' Vistide (cidofovir injection), its FDA-approved treatment for CMV retinitis in AIDS patients for a potential $60mm in cash and equity purchases.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Includes Equity

Related Companies